Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
These Are the 3 Biggest Bargains in Biotech | The Motley Fool
11:21am, Wednesday, 07'th Oct 2020
Drug developers don't get much cheaper than this.
Why Exelixis Jumped 10% in September | The Motley Fool
06:23pm, Tuesday, 06'th Oct 2020
The biotech was the beneficiary of a string of positive developments.
Next Coronavirus Market Crash: Where to Invest $10,000 | The Motley Fool
10:55am, Saturday, 03'rd Oct 2020
Prep your portfolio by buying shares of healthcare companies that can deliver revenue growth in the worst of times.
Researchers Look for New Ways to Boost Diagnostic Capabilities
01:01pm, Friday, 02'nd Oct 2020
NEW YORK, Oct. 2, 2020 (PR Newswire Europe via COMTEX) --
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- The global cancer diagnostics market is of the more...
Researchers Look for New Ways to Boost Diagnostic Capabilities
01:00pm, Friday, 02'nd Oct 2020
NEW YORK, Oct. 2, 2020 /PRNewswire via COMTEX/ --
NEW YORK, Oct. 2, 2020 /PRNewswire/ -- The global cancer diagnostics market is of the more innovative...
The 3 Best Stocks to Invest $100 in Right Now | The Motley Fool
09:51am, Friday, 02'nd Oct 2020
You don't need a fortune to begin charting a path toward financial independence.
Exelixis: Good News And Bad Plus Stubborn Stock Price Makes Investment Case Less Attractive (NASDAQ:EXEL)
12:57pm, Monday, 28'th Sep 2020
Exelixis stock has been up and down on news of progress of Checkmate 9-ER trial evaluating lead candidate Cabometyx and Opdivo in RCC.
Exelixis Cabozantinib Data, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:EXEL)
05:55am, Friday, 25'th Sep 2020
Exelixis reports data from COSMIC-021 trial of Cabozantinib. Agios reports final overall survival data for Tibsovo.
Mixed Data From ESMO Sets Up The Next Fight For Exelixis (NASDAQ:EXEL)
04:54pm, Thursday, 24'th Sep 2020
The CheckMate-9ER of Cabometyx and Opdivo was successful, but not definitively superior to the established combo of Pfizer's Inlyta and Merck's Keytruda.
Sei Investments Co. Takes $3.28 Million Position in Exelixis, Inc. (NASDAQ:EXEL)
09:01am, Wednesday, 23'rd Sep 2020
Sei Investments Co. bought a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the second quarter, HoldingsChannel.com reports. The fund bought 137,443 shares of the biotechnology company’s stock, va
Exelixis (NASDAQ:EXEL) PT Raised to $37.00 at Oppenheimer
03:58am, Tuesday, 22'nd Sep 2020
Exelixis (NASDAQ:EXEL) had its price target raised by Oppenheimer from $33.00 to $37.00 in a report published on Monday, Benzinga reports. Oppenheimer currently has an outperform rating on the biotech
Needham Believes Exelixis (NASDAQ: EXEL) Won't Stop Here - Markets
10:57am, Monday, 21'st Sep 2020
In a report released today, Chad Messer from Needham assigned a Buy rating to Exelixis (EXEL – Research Report), with
Exelixis, Inc. (NASDAQ: EXEL) today announced positive phase 1b clinical trial results for the combination of cabozantinib (CABOMETYX®) and atezolizum
Stifel Financial Corp Sells 2,476 Shares of Exelixis, Inc. (NASDAQ:EXEL)
07:25am, Saturday, 19'th Sep 2020
Stifel Financial Corp reduced its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 2.4% in the 2nd quarter, HoldingsChannel reports. The firm owned 98,760 shares of the biotechnology company’s
